BioArctic AB (publ) (STO:BIOA.B)
322.60
+6.80 (2.15%)
Jul 28, 2026, 5:29 PM CET
BioArctic AB Revenue
BioArctic AB had revenue of 437.59M SEK in the quarter ending March 31, 2026, a decrease of -66.07%. This brings the company's revenue in the last twelve months to 1.15B, down -24.40% year-over-year. In the year 2025, BioArctic AB had annual revenue of 2.00B with 676.80% growth.
Revenue (ttm)
1.15B
Revenue Growth
-24.40%
P/S Ratio
24.43
Revenue / Employee
8.14M
Employees
141
Market Cap
28.02B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.00B | 1.74B | 676.80% |
| Dec 31, 2024 | 257.35M | -358.64M | -58.22% |
| Dec 31, 2023 | 616.00M | 386.56M | 168.49% |
| Dec 31, 2022 | 229.43M | 203.77M | 794.02% |
| Dec 31, 2021 | 25.66M | -39.54M | -60.64% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Camurus AB | 2.27B |
| Saniona AB | 429.29M |
| BioInvent International AB | 217.86M |
| Hansa Biopharma AB | 189.46M |
| Genovis AB (publ.) | 136.99M |
| Egetis Therapeutics AB | 63.10M |
| Medivir AB | 9.01M |
| Vicore Pharma Holding AB | 3.53M |
BioArctic AB News
- 14 days ago - More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026 - PRNewsWire
- 14 days ago - FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease - PRNewsWire
- 15 days ago - New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease - PRNewsWire
- 4 weeks ago - New clinical and real-world evidence on Lecanemab to be presented at AAIC conference 2026 - PRNewsWire
- 5 weeks ago - BioArctic AB Press release: Collaboration - Filings
- 5 weeks ago - BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic's BrainTransporter™ technology - PRNewsWire
- 2 months ago - Number of shares and votes in BioArctic AB (publ) as of May 29, 2026 - PRNewsWire
- 2 months ago - Bulletin from the Annual General Meeting in BioArctic AB (publ) - PRNewsWire